BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30721246)

  • 1. Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma.
    Van Laar R; Lincoln M; Fereday S
    PLoS One; 2019; 14(2):e0211504. PubMed ID: 30721246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.
    Laar RV; King S; McCoy R; Saad M; Fereday S; Winship I; Uzzell C; Landgren A
    Biomark Med; 2021 Sep; 15(13):1111-1122. PubMed ID: 34184547
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Van Laar R; Latif B; King S; Love C; Taubenheim N; Kalansooriya E; Wang W; Saad M; Winship I; Azzi A; Lilleyman A; Landgren T
    Br J Dermatol; 2023 Aug; 189(3):292-301. PubMed ID: 37144735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
    van Laar RK; Lincoln MT; van Laar BJ
    Melanoma Res; 2019 Feb; 29(1):19-22. PubMed ID: 30320629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information.
    Jayawardana K; Schramm SJ; Haydu L; Thompson JF; Scolyer RA; Mann GJ; Müller S; Yang JY
    Int J Cancer; 2015 Feb; 136(4):863-74. PubMed ID: 24975271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma.
    Maiques O; Macià A; Moreno S; Barceló C; Santacana M; Vea A; Herreros J; Gatius S; Ortega E; Valls J; Chen BJ; Llobet-Navas D; Matias-Guiu X; Cantí C; Marti RM
    Br J Dermatol; 2017 May; 176(5):1247-1258. PubMed ID: 27718503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
    Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
    Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma.
    Jiang L; Lv X; Li J; Li J; Li X; Li W; Li Y
    Acta Histochem; 2012 Oct; 114(6):582-8. PubMed ID: 22130252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
    Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
    Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
    Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
    [No Abstract]   [Full Text] [Related]  

  • 11. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Biomarkers in Cutaneous Melanoma.
    Eisenstein A; Gonzalez EC; Raghunathan R; Xu X; Wu M; McLean EO; McGee J; Ryu B; Alani RM
    Mol Diagn Ther; 2018 Apr; 22(2):203-218. PubMed ID: 29411301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLURP-1 is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene.
    Bergqvist C; Kadara H; Hamie L; Nemer G; Safi R; Karouni M; Marrouche N; Abbas O; Hasbani DJ; Kibbi AG; Nassar D; Shimomura Y; Kurban M
    Int J Dermatol; 2018 Feb; 57(2):162-170. PubMed ID: 29231248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel microRNA signature for the detection of melanoma by liquid biopsy.
    Sabato C; Noviello TMR; Covre A; Coral S; Caruso FP; Besharat ZM; Splendiani E; Masuelli L; Battistelli C; Vacca A; Catanzaro G; Po A; Anichini A; Maio M; Ceccarelli M; Di Giacomo AM; Ferretti E
    J Transl Med; 2022 Oct; 20(1):469. PubMed ID: 36243798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
    Wu ZS; Cheng XW; Wang XN; Song NJ
    Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in cutaneous melanoma: Role as diagnostic and prognostic biomarkers.
    Ross CL; Kaushik S; Valdes-Rodriguez R; Anvekar R
    J Cell Physiol; 2018 Jul; 233(7):5133-5141. PubMed ID: 29226953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
    Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF
    Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.
    Xu L; Fengji L; Changning L; Liangcai Z; Yinghui L; Yu L; Shanguang C; Jianghui X
    PLoS One; 2015; 10(11):e0142433. PubMed ID: 26606135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
    Kunter U; Buer J; Probst M; Duensing S; Dallmann I; Grosse J; Kirchner H; Schluepen EM; Volkenandt M; Ganser A; Atzpodien J
    J Natl Cancer Inst; 1996 May; 88(9):590-4. PubMed ID: 8609659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
    Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
    Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.